Drug Profile
Research programme: mitochondrial dysfunction therapeutics - Immungenetics
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Immungenetics
- Class Antidementias; Antihypertensives; Antipsoriatics; Antirheumatics; Obesity therapies; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Arterial occlusive disorders; Gastroenteritis; Hypertension; Multiple sclerosis; Obesity; Pancreatitis; Pemphigus; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus; Type 2 diabetes mellitus
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in Germany
- 28 Mar 2022 No recent reports of development identified for preclinical development in Arterial-occlusive-disorders in Germany
- 28 Mar 2022 No recent reports of development identified for preclinical development in Gastroenteritis in Germany